AOD-9604 + MOTS-c Stack: Safety Monitoring Guide

Why there is no monitoring protocol to follow

Neither peptide has an FDA-approved label. AOD-9604 has limited human evidence from an oral obesity study that failed its primary weight-loss endpoint, while FDA found no published study in which MOTS-c was administered to a person [1][2].

AOD-9604 never reached approval: it was in phase IIa trials by February 2002, and the obesity program was later dropped [4][1]. MOTS-c is not an approved drug or a component of one, and FDA's review found no animal toxicity studies for it [2].

What FDA has said about each peptide

Both peptides appear in FDA's table of bulk substances that were previously in category 2 and whose nominators withdrew them. FDA's page states that removal from category 2 was not a finding that a substance is safe [3].

For AOD-9604, FDA's stated concerns are immunogenicity risk for certain routes of administration from peptide impurities and characterization problems; no, or only limited, safety information; and serious adverse events that may be associated with AOD-9604, though causality is not clear [3]. FDA does not name the events.

For MOTS-c, FDA states that it lacks important safety information and that injectable peptides may pose immunogenicity risk because of aggregation and impurities [3]. Its searches of the adverse-event database FAERS through March 9, 2025 retrieved no MOTS-c reports, and its review noted an in-vitro finding that MOTS-c is broken down quickly in human blood, raising the question whether injecting it can produce active levels in people [2]. A database with no reports, for a product with no recorded human exposure, cannot show that the product is safe.

What the animal data show, and what they do not

In obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days cut body-weight gain to 15.8 g versus 35.6 g in controls, raised fat-tissue lipolytic activity and, unlike growth hormone, did not worsen insulin sensitivity measured by euglycemic clamp [9]. In obese mice, 14 days of intraperitoneal injections reduced body weight and fat and raised beta-3 adrenergic receptor RNA; in mice lacking that receptor, the long-term effects were not seen, and the authors concluded that the lipolytic actions are not mediated directly through the beta-3 receptor [10]. Preclinical work found no growth-hormone-receptor binding [1].

In mice, injected MOTS-c lowered weight gain on a high-fat diet — about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneal — and improved insulin sensitivity and exercise performance; a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [2]. The 2015 discovery paper reported that MOTS-c treatment prevented age-dependent and diet-induced insulin resistance and diet-induced obesity in mice, with skeletal muscle as the main target [6]. In a 2021 study, MOTS-c injection improved physical performance in young, middle-aged and old mice; in people, the same study only measured that exercise raises the body's own MOTS-c [11]. A randomized trial of 30 healthy adults found a trend for plasma MOTS-c to rise after endurance exercise, and nobody in it received MOTS-c [12].

Rodent doses of 0.5 to 15 mg/kg cannot be converted into human doses [2], and none of these measurements identifies a lab value to follow in a person receiving injections.

What the human AOD-9604 record covers

Human evidence on AOD-9604 is limited and largely short-term [1]. A 2026 review describes a 24-week oral AOD-9604 obesity study (502 randomized) that failed to show a significant benefit on its primary weight-loss endpoint; the result rests on sponsor-reported phase 2 findings rather than a peer-reviewed randomized trial, and the review notes no robust human data for visceral-fat reduction or other metabolic benefit [1]. That study tested an oral drug candidate [1].

What can actually be watched

Two things have a basis in what FDA says. First, injectable products containing these peptides may pose an immunogenicity risk, meaning an immune reaction to the peptide itself or to impurities and aggregates in the product [3][2]. Second, FDA says it identified serious adverse events that may be associated with AOD-9604 but published no details and did not establish causality [3]. For MOTS-c, safety in humans is unknown [2].

Can routine blood tests catch a problem early?

No lab marker linked to harm from either peptide appears in FDA's reviews of these two peptides or in the human AOD-9604 record, which is a failed oral obesity trial summarized from sponsor results [3][2][1]. MOTS-c has no human safety data [2].

Checking the product, and the rules around it

Product documentation is the part that can be checked. Under the federal compounding framework, bulk drug substances must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA [7]. HHS's draft enforcement-discretion policy for six peptides — MOTS-c among them, as the acetate salt, injected subcutaneously or intramuscularly — lists conditions including a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [13][14]. That policy is a draft, does not establish rights for any person, is not binding on HHS or the public, and is not an approval or a listing [13].

AOD-9604 is not one of the six peptides and is not covered by that draft [13]. Neither peptide appears in any of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025) [15][16][7]. MOTS-c's position moved in July 2026, when FDA's Pharmacy Compounding Advisory Committee voted in favor of adding it to the compounding bulks list, against FDA staff's recommendation; that vote is advice only and not binding, and MOTS-c is not on the list [17][13]. FDA staff had recommended against listing it, citing among other things that it is not well characterized and has no human safety or effectiveness data and no animal toxicity studies [2]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [13].

WADA's Prohibited List names AOD-9604 and hGH 176-191 in S2.2.3 and MOTS-c in S4.4.1; both are prohibited at all times, in and out of competition, on the 2026 List and the 2027 List [8][18].

What remains unknown

• Whether either peptide is safe in humans over any period: MOTS-c has no human safety data [2], and AOD-9604's human record is short-term and partly sponsor-reported [1].
• What the serious adverse events FDA mentions for AOD-9604 actually were [3].
• Whether injecting MOTS-c produces active blood levels, given its rapid breakdown in human blood in vitro and the absence of pharmacokinetic data in humans or live animals [2].